Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP961642priorityCriticalpatent/ECSP961642A/en
Publication of ECSP961642ApublicationCriticalpatent/ECSP961642A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se obtienen purin-6-onas bisustituidas en 2,9, acilando en una primera etapa los correspondientes aminoimidazoles sustituidos correspondientes y ciclando, después de esto, para obtener la purina. Las nuevas purin-6-onas bisustituidas en 2, 9 pueden emplearse como sustancia activa en medicamentos, especialmente para el tratamiento de inflamaciones, enfermedades tromboembólicas, del corazón y de la circulación y enfermedades del sistema urogenital.2.9-bisubstituted purin-6-ones are obtained by acylating in a first step the corresponding corresponding substituted aminoimidazoles and cyclizing thereafter to obtain purine. The new purin-6-ones bisubstituted in 2, 9 can be used as an active substance in medicines, especially for the treatment of inflammations, thromboembolic, heart and circulation diseases and diseases of the urogenital system.